• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.530 +0.030 (+2.00%)
Streaming Delayed Price Updated: 9:36 AM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,915
Open 1.510
Bid (Size) 1.530 (600)
Ask (Size) 1.540 (800)
Prev. Close 1.500
Today's Range 1.510 - 1.535
52wk Range 1.070 - 6.175
Shares Outstanding 58,576,350
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.
April 29, 2026
From Robbins LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
April 28, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-67.2%
-67.2%
1 Month
-8.9%
-8.9%
3 Month
-71.8%
-71.8%
6 Month
-69.7%
-69.7%
1 Year
-43.1%
-43.1%

More News

Read More
News headline image
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
April 28, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 28, 2026
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
April 27, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
April 24, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 24, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
April 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 21, 2026
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
April 18, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 17, 2026
From Schall Law
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their Rights
April 15, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
April 14, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 14, 2026
From Schall Law
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 10, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
April 07, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 07, 2026
From Schall Law
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 03, 2026
From Schall Law
Via GlobeNewswire
News headline image
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
April 02, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
April 01, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALDX
April 01, 2026
From The DJS Law Group
Via Business Wire
News headline image
INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP
March 31, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
March 31, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 31, 2026
From The Schall Law Firm
Via Business Wire
News headline image
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
March 31, 2026
From Faruqi & Faruqi, LLP
Via Business Wire

Frequently Asked Questions

Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?
Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?
The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market
What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?
The current price of Aldeyra Therapeutics, Inc. - Common Stock is 1.530
When was Aldeyra Therapeutics, Inc. - Common Stock last traded?
The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 04/30/26 09:36 AM ET
What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?
The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 89.62M
How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?
Aldeyra Therapeutics, Inc. - Common Stock has 90M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap